News articles about Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) have trended somewhat positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inotek Pharmaceuticals Corporation earned a news impact score of 0.21 on AlphaOne’s scale. AlphaOne also gave news stories about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Alpha One’s scoring:

Insider Buying and Selling by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)

A number of research analysts have issued reports on ITEK shares. Canaccord Genuity set a $3.00 target price on shares of Inotek Pharmaceuticals Corporation and gave the company a “buy” rating in a research note on Thursday, March 16th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Inotek Pharmaceuticals Corporation in a research note on Friday, March 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.75.

Shares of Inotek Pharmaceuticals Corporation (ITEK) traded down 2.597% during mid-day trading on Friday, hitting $1.875. 401,967 shares of the stock were exchanged. The firm’s market cap is $50.60 million. Inotek Pharmaceuticals Corporation has a 1-year low of $1.50 and a 1-year high of $9.90. The company’s 50-day moving average is $1.80 and its 200-day moving average is $2.59.

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last issued its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.01. Equities research analysts anticipate that Inotek Pharmaceuticals Corporation will post ($1.70) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Inotek Pharmaceuticals Corporation (ITEK) Getting Somewhat Positive News Coverage, AlphaOne Reports” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.